CD14 and tuberculosis: Specifically, quantification of PD-L1 expression on CD14- CD16+ monocytes, in combination with transcriptional profiling of TCOF1 and LMO2, may serve as a composite biomarker panel to stratify TB progression risk in patients undergoing PD-L1 inhibitor therapy.